De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review)

Fabrizio Fabrizi, Alessio Aghemo, Gabriella Moroni, Patrizia Passerini, Roberta D'Ambrosio, Paul Martin, Piergiorgio Messa

Research output: Contribution to journalArticle

3 Scopus citations


HCV infects approximately 2-3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].

Original languageEnglish (US)
Pages (from-to)691-695
Number of pages5
JournalDigestive Diseases and Sciences
Issue number3
StatePublished - Mar 1 2014



  • Hepatitis C
  • Interferon
  • Membrano-proliferative glomerulonephritis
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this